{"doc_id": "si-2023-0422-reg-1", "parent_doc_id": "si-2023-0422", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 422 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n\n(Prescription and Control of Supply) (Amendment) (No. 5) Regulations 2023. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2023” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 5) regulation 2023 (2) collective citation medicinal product (prescription control supply) regulation 2003 2023 includes regulation", "start_char": 622, "end_char": 912, "source_path": "downloads\\2023\\2023_0422.pdf", "extraction_method": "pdfminer", "checksum": "sha256:73c023745d56e48d8b1d704ae4d748f96f44caa88db5f27ac553bd46bbdecaf6", "cross_refs": []}
{"doc_id": "si-2023-0422-reg-2", "parent_doc_id": "si-2023-0422", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 422 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and Control \nof Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2023” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 4) Regulations 2023 (S.I. No. 284 of 2023).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2023 mean medicinal product (prescription control supply) (amendment) (no 4) regulation 2023 (s.i no 284 2023)", "start_char": 912, "end_char": 1227, "source_path": "downloads\\2023\\2023_0422.pdf", "extraction_method": "pdfminer", "checksum": "sha256:73c023745d56e48d8b1d704ae4d748f96f44caa88db5f27ac553bd46bbdecaf6", "cross_refs": []}
{"doc_id": "si-2023-0422-reg-3", "parent_doc_id": "si-2023-0422", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 422 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "3. Regulation 4F (as amended by Regulation 4 of the Regulations of 2023)", "text_raw": "3. Regulation 4F (as amended by Regulation 4 of the Regulations of 2023) \n\nof the Principal Regulations is amended— \n\n(a) \n\nby substituting for the heading the following: \n\n“Supply and administration of certain medicinal products by \ncertain health professionals as part of HSE vaccination \nprogramme”, \n\n(b) by substituting for paragraph (a) the following: \n\n“(a) \n\nthe medicinal product is supplied and administered as part \nof a vaccination programme that is being coordinated, \noverseen and implemented in the State by the Health \nService Executive for the purpose of immunising members \nof the public against an infectious disease that is listed in \nthe Schedule to the Infectious Diseases Regulations 1981 \n(S.I. No. 390 of 1981), including where a public health \nemergency has been declared,”, and \n\n(c) \n\nin paragraph (b), by inserting “or as provided by another body \nrecognised by the said regulatory body for this purpose” after “the \nprofession concerned”.", "text_norm": "3 regulation 4f (as amended regulation 4 regulation 2023) principal regulation amended-- (a) substituting heading following supply administration certain medicinal product certain health professional part hse vaccination programme (b) substituting paragraph (a) following (a) medicinal product supplied administered part vaccination programme coordinated overseen implemented state health service executive purpose immunising member public infectious disease listed schedule infectious disease regulation 1981 (s.i no 390 1981) including public health emergency declared (c) paragraph (b) inserting provided another body recognised said regulatory body purpose profession concerned", "start_char": 1227, "end_char": 2198, "source_path": "downloads\\2023\\2023_0422.pdf", "extraction_method": "pdfminer", "checksum": "sha256:73c023745d56e48d8b1d704ae4d748f96f44caa88db5f27ac553bd46bbdecaf6", "cross_refs": []}
{"doc_id": "si-2023-0422-reg-4", "parent_doc_id": "si-2023-0422", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 422 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "4. The Principal Regulations are amended by revoking Regulation 4G.", "text_raw": "4. The Principal Regulations are amended by revoking Regulation 4G. \n\nNotice of the making of this Statutory Instrument was published in \n\"Iris Oifigiúil\" of 29th August, 2023. \n\n \n \n \n \n \n \n \n \n\f[422] 3", "text_norm": "4 principal regulation amended revoking regulation 4g notice making statutory instrument published iris oifigiuil 29th august 2023 422 3", "start_char": 2198, "end_char": 2404, "source_path": "downloads\\2023\\2023_0422.pdf", "extraction_method": "pdfminer", "checksum": "sha256:73c023745d56e48d8b1d704ae4d748f96f44caa88db5f27ac553bd46bbdecaf6", "cross_refs": []}
{"doc_id": "si-2023-0422-reg-5", "parent_doc_id": "si-2023-0422", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 422 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "5. Regulation 10D (as amended by Regulation 5 of the Medicinal Products", "text_raw": "5. Regulation 10D (as amended by Regulation 5 of the Medicinal Products \n(Prescription and Control of Supply) (Amendment) (No. 7) Regulations 2021 \n(S.I. No. 245 of 2021)) of the Principal Regulations is amended— \n\n(a) \n\nin the heading, by substituting “medicinal products under \nRegulation 4F” for “Covid-19 vaccination”, \n\n(b) by deleting “or Regulation 4G”, and \n\n(c) \n\nby substituting for paragraphs (f) and (fa) the following \nparagraph: \n\n“(f) \n\nthe name, business address, email and telephone number of \nthe person who supplied and administered the product and \nthe number of his or her certificate of registration issued by \nhis or her professional regulatory body;”.", "text_norm": "5 regulation 10d (as amended regulation 5 medicinal product (prescription control supply) (amendment) (no 7) regulation 2021 (s.i no 245 2021)) principal regulation amended-- (a) heading substituting medicinal product regulation 4f covid-19 vaccination (b) deleting regulation 4g (c) substituting paragraph (f) (fa) following paragraph (f) name business address email telephone number person supplied administered product number certificate registration issued professional regulatory body", "start_char": 2404, "end_char": 3082, "source_path": "downloads\\2023\\2023_0422.pdf", "extraction_method": "pdfminer", "checksum": "sha256:73c023745d56e48d8b1d704ae4d748f96f44caa88db5f27ac553bd46bbdecaf6", "cross_refs": []}
{"doc_id": "si-2023-0422-reg-6", "parent_doc_id": "si-2023-0422", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 422 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "6. The Twelfth Schedule (as amended by Regulation 9 of the Regulations", "text_raw": "6. The Twelfth Schedule (as amended by Regulation 9 of the Regulations \nof 2023) to the Principal Regulations is amended by inserting the following \nentries: \n\n“ \n\nMedicinal \nproduct \n\nRoute of \nadministratio\nn \n\nForm and \npresentation \nof product \nadministere\nd \n\nDosage and \nconditions of \nadministratio\nn \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministere\nd \n\nColumn 1 Column 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nInfluenza \nvaccine \n(live \nattenuated) \nnasal spray \nsuspension \nof a \ncompositio\nn that has \nbeen \napproved \nfor use in \nthe \nEuropean \nUnion for \nthe season \nin question \n\nNasal spray, \nsuspension. \n\nBy intranasal \nadministration \nonly. \n\nPrevention \nof seasonal \ninfluenza. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee. \n\n \n \n \n\fIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministere\nd \n\nVaccination \nagainst \nvaricella. \n\n4 [422] \n\nMedicinal \nproduct \n\nRoute of \nadministratio\nn \n\nForm and \npresentation \nof product \nadministere\nd \n\nIntramuscular \nor \nsubcutaneous \ninjection. \n\nVARIVA\nX powder \nand solvent \nfor \nsuspension \nfor \ninjection in \na pre-filled \nsyringe \nVaricella \nVaccine \n(live) \n\nPowder and \nsolvent for \nsuspension \nfor injection. \nWhite to offwhite \npowder and \nclear, \ncolourless \nliquid \nsolvent. \n\nIMVANE\nX \nsuspension \nfor \ninjection \nSmallpox \nand \nmonkeypo\nx vaccine \n(Live \nModified \nVaccinia \nVirus \nAnkara) \n\nBCG \nVACCINE \nAJV \n\nSubcutaneous \ninjection. \n\nSuspension \nfor injection. \nLight yellow \nto pale \nwhite, milky \nsuspension. \n\nActive \nimmunisatio\nn against \nsmallpox, \nmonkeypox \nand disease \ncaused by \nvaccinia \nvirus in \nadults. \n\nIntradermal \ninjection. \n\nActive \nimmunisatio\nn against \ntuberculosis. \n\nPowder and \nsolvent for \nsuspension \nfor injection. \nWhite \ncrystalline \npowder \n\nDosage and \nconditions of \nadministratio\nn \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \n\n \n\fMedicinal \nproduct \n\nRoute of \nadministratio\nn \n\nForm and \npresentation \nof product \nadministere\nd \n\n[422] 5 \n\nDosage and \nconditions of \nadministratio\nn \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministere\nd \n\n(might be \ndifficult to \nsee due to \nthe small \namount of \npowder in \nthe vial). \nThe solvent \nis a \ncolourless \nsolution \nwithout any \nvisible \nparticles. \n\nSolution for \ninjection \n(injection). \nClear, \ncolourless to \npale-yellow \nsolution. \n\nTuberculin \nPPD RT23 \n2 T.U./0.1 \nmL \n\nIntradermal \ninjection. \n\nUsed for \nMantoux \ntuberculin \nskin testing. \n\nM-M-R \nvaxPro \npowder \nand solvent \nfor \nsuspension \nfor \ninjection \n\nPowder and \nsolvent for \nsuspension \nfor injection. \nBefore \nreconstitutio\nn, the \npowder is a \n\nIntramuscular \nor \nsubcutaneous \ninjection. \n\nVaccination \nagainst \nmeasles, \nmumps and \nrubella. \n\nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee. \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \n\n \n \n \n\f6 [422] \n\nMedicinal \nproduct \n\nMeasles, \nMumps \nand \nRubella \nvaccine \n(live) \n\nPriorix - \nPowder \nand solvent \nfor \nsolution \nfor \ninjection in \na pre-filled \nsyringe \nMeasles, \nMumps \nand \nRubella \nvaccine \n(live) \n\n”. \n\nRoute of \nadministratio\nn \n\nForm and \npresentation \nof product \nadministere\nd \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadministere\nd \n\nlight yellow \ncompact \ncrystalline \ncake and the \nsolvent is a \nclear \ncolourless \nliquid. \n\nPowder and \nsolvent for \nsolution for \ninjection in a \npre-filled \nsyringe. \n\nSubcutaneous \nor \nintramuscular \ninjection. \n\nActive \nimmunisatio\nn against \nMeasles, \nMumps and \nRubella. \n\nDosage and \nconditions of \nadministratio\nn \n\nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand/or \nrelevant \nnational \nguidelines \nissued by the \nNational \nImmunisation \nAdvisory \nCommittee. \n\nGIVEN under my Official Seal, \n\n23 August, 2023. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n\f[422] 7", "text_norm": "6 twelfth schedule (as amended regulation 9 regulation 2023) principal regulation amended inserting following entry medicinal product route administratio n form presentation product administere dosage condition administratio n indication medicinal product may administere column 1 column 2 column 3 column 4 column 5 influenza vaccine (live attenuated) nasal spray suspension compositio n approved use european union season question nasal spray suspension intranasal administration only prevention seasonal influenza accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee indication medicinal product may administere vaccination varicella 4 422 medicinal product route administratio n form presentation product administere intramuscular subcutaneous injection variva x powder solvent suspension injection pre-filled syringe varicella vaccine (live) powder solvent suspension injection white offwhite powder clear colourless liquid solvent imvane x suspension injection smallpox monkeypo x vaccine (live modified vaccinia virus ankara) bcg vaccine ajv subcutaneous injection suspension injection light yellow pale white milky suspension active immunisatio n smallpox monkeypox disease caused vaccinia virus adult intradermal injection active immunisatio n tuberculosis powder solvent suspension injection white crystalline powder dosage condition administratio n accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee accordance summary product characteristic product administered medicinal product route administratio n form presentation product administere 422 5 dosage condition administratio n indication medicinal product may administere (might difficult see due small amount powder vial) solvent colourless solution without visible particle solution injection (injection) clear colourless pale-yellow solution tuberculin ppd rt23 2 t.u 0.1 ml intradermal injection used mantoux tuberculin skin testing m-m-r vaxpro powder solvent suspension injection powder solvent suspension injection reconstitutio n powder intramuscular subcutaneous injection vaccination measles mumps rubella relevant national guideline issued national immunisation advisory committee accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee accordance summary product characteristic product administered 6 422 medicinal product measles mumps rubella vaccine (live) priorix - powder solvent solution injection pre-filled syringe measles mumps rubella vaccine (live)  route administratio n form presentation product administere indication medicinal product may administere light yellow compact crystalline cake solvent clear colourless liquid powder solvent solution injection pre-filled syringe subcutaneous intramuscular injection active immunisatio n measles mumps rubella dosage condition administratio n relevant national guideline issued national immunisation advisory committee accordance summary product characteristic product administered relevant national guideline issued national immunisation advisory committee given official seal 23 august 2023 stephen donnelly minister health 422 7", "start_char": 3082, "end_char": 7908, "source_path": "downloads\\2023\\2023_0422.pdf", "extraction_method": "pdfminer", "checksum": "sha256:73c023745d56e48d8b1d704ae4d748f96f44caa88db5f27ac553bd46bbdecaf6", "cross_refs": []}
{"doc_id": "si-2023-0422-explanatory-note", "parent_doc_id": "si-2023-0422", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 422 of 2023", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2023, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to provide for the supply and administration \nof medicinal products as part of HSE vaccination programmes under Regulation \n4F, to add additional products to the list of products to which that provision \napplies and to update and remove other provisions introduced in response to the \nCovid-19 pandemic. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 5) Regulations 2023. \n\n \n \n \n \n \n \n \n\f8 [422] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 3.00 \n\n(DH-499) 75. 8/23. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation provide supply administration medicinal product part hse vaccination programme regulation 4f add additional product list product provision applies update remove provision introduced response covid-19 pandemic regulation may cited medicinal product (prescription control supply) (amendment) (no 5) regulation 2023 8 422 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 3.00 (dh-499) 75 8 23 propylon", "start_char": 7908, "end_char": 9113, "source_path": "downloads\\2023\\2023_0422.pdf", "extraction_method": "pdfminer", "checksum": "sha256:73c023745d56e48d8b1d704ae4d748f96f44caa88db5f27ac553bd46bbdecaf6", "cross_refs": []}
